Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entresto in advanced heart failure
NCT02816736Phase 4Completed
- Sponsor
- Duke University
- Start
- Mar 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), sponsored by Duke University. Started Mar 2017; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02816736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02816736.